Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Miramar Cosmetics, Inc.
WARNING LETTER
•Miramar Cosmetics, Inc.•February 14, 2011

Miramar Cosmetics, Inc. – FDA Warning Letter, Feb 14, 2011

Record Details

An FDA inspection of Miramar Cosmetics, Inc. from February 4-14, 2011, revealed significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals, rendering drug products adulterated under 21 U.S.C. § 351(a)(2)(B). Additionally, the firm's Over-the-Counter (OTC) drug products are unapproved new drugs, violating 21 U.S.C. §§ 331(d) and 355(a), and are misbranded under 21 U.S.C. §§ 352(c), (e), and (o). The FDA acknowledged the firm's late response to the Form FDA 483.

CGMP violations, many repeated from a 2007 inspection, included failure to establish procedures for preventing objectionable microorganisms (21 CFR § 211.113(a)), lack of specifications and laboratory controls (21 CFR § 211.160(a)), inadequate laboratory testing (21 CFR § 211.165(b)), and incomplete batch production records (21 CFR § 211.188). These repeat observations indicate a deficient quality control unit. The firm's OTC products (HONGOTRIM LIQUID SOAP, HONGOTRIM SPRAY, ARTHRI SOLUTION CREAM, ARTHRI Life CREAM, Yesoterapia Reductor Cream) are considered unapproved new drugs and misbranded due to non-conformance with monographs, lack of Drug Facts panels, failure to list/distinguish active ingredients, and inconsistent bilingual labeling. Furthermore, all five products are misbranded for not being manufactured in a registered establishment or included in a required list.

The FDA recommends engaging a third-party CGMP consultant and requires prompt corrective actions. The firm must notify the FDA within fifteen working days of steps taken, including discontinuing marketing of unapproved drugs and updating Drug Listing files. Quarterly reports are requested to assess progress. Failure to correct violations may lead to legal action, including seizure and injunction, and impact federal contracts or drug application approvals.

Company
Miramar Cosmetics, Inc.
Inspection date
February 14, 2011
Product type
Drugs
Office
Florida District Office
People
  • Andrea H. Norwood (Investigator )
  • Elizabeth W. Ormond
View Company Profile

ID · 8f65c1b9-4b0f-48a9-9ff9-374967e74d2e

Violation Codes10
21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 U.S.C. 351(a)(2)(B)21 U.S.C. 331(d)21 U.S.C. 355(a)21 U.S.C. 352(c)21 U.S.C. 352(e)21 U.S.C. 352(o)21 CFR 211.113(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Miramar Cosmetics, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.